Trial Design for Obese: Right Compound, Right Dose, Right Patient

The presentation will explore how physiologically-based pharmacokinetic (PBPK) models can be adapted for better understanding and managing drug therapies in obese populations. Obesity significantly alters body composition and organ functions, necessitating tailored approaches for predicting drug behavior. PBPK modeling, which simulates the body's absorption, distribution, metabolism, and excretion of drugs, offers a promising tool to predict how these changes impact pharmacokinetics in obese individuals. The session will discuss the current state of PBPK modeling for obese populations, limitations in existing models, and advancements needed for more accurate predictions. Practical examples from both clinical and preclinical data will highlight the gaps in knowledge and the potential of PBPK to enhance drug safety and efficacy for obese patients. Attendees will gain insights into current challenges and innovative strategies to refine PBPK models, ultimately contributing to more personalized and effective treatment regimens for obese individuals.